Compare SUVEN LIFE with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES FRESENIUS KABI ONCO. SUVEN LIFESCIENCES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 19.2 22.1 86.7% View Chart
P/BV x 3.9 3.1 124.9% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFESCIENCES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
FRESENIUS KABI ONCO.
Mar-13
SUVEN LIFESCIENCES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs338176 191.9%   
Low Rs16979 215.8%   
Sales per share (Unadj.) Rs52.137.7 138.3%  
Earnings per share (Unadj.) Rs6.85.1 134.1%  
Cash flow per share (Unadj.) Rs8.66.7 127.5%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.342.5 153.5%  
Shares outstanding (eoy) m127.28158.23 80.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.4 144.0%   
Avg P/E ratio x37.125.0 148.6%  
P/CF ratio (eoy) x29.618.9 156.3%  
Price / Book Value ratio x3.93.0 129.8%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,27220,135 160.3%   
No. of employees `0001.11.2 93.9%   
Total wages/salary Rs m661703 94.0%   
Avg. sales/employee Rs Th6,132.25,176.2 118.5%   
Avg. wages/employee Rs Th611.1610.4 100.1%   
Avg. net profit/employee Rs Th803.5699.6 114.9%   
INCOME DATA
Net Sales Rs m6,6355,963 111.3%  
Other income Rs m24218 1,346.1%   
Total revenues Rs m6,8775,981 115.0%   
Gross profit Rs m1,6041,430 112.2%  
Depreciation Rs m221258 85.8%   
Interest Rs m38-26 -145.0%   
Profit before tax Rs m1,5871,216 130.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m718342 209.8%   
Profit after tax Rs m869806 107.9%  
Gross profit margin %24.224.0 100.8%  
Effective tax rate %45.228.1 160.8%   
Net profit margin %13.113.5 97.0%  
BALANCE SHEET DATA
Current assets Rs m6,2325,102 122.2%   
Current liabilities Rs m1,4902,385 62.5%   
Net working cap to sales %71.545.6 156.9%  
Current ratio x4.22.1 195.6%  
Inventory Days Days86150 57.6%  
Debtors Days Days83113 72.9%  
Net fixed assets Rs m4,0435,148 78.5%   
Share capital Rs m127158 80.5%   
"Free" reserves Rs m8,1836,556 124.8%   
Net worth Rs m8,3106,732 123.4%   
Long term debt Rs m18952 1.9%   
Total assets Rs m10,38910,388 100.0%  
Interest coverage x43.1-45.8 -94.2%   
Debt to equity ratio x00.1 1.5%  
Sales to assets ratio x0.60.6 111.3%   
Return on assets %8.77.5 116.3%  
Return on equity %10.512.0 87.4%  
Return on capital %19.514.6 133.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m5,6225,298 106.1%   
Fx outflow Rs m1,7991,772 101.5%   
Net fx Rs m3,8223,525 108.4%   
CASH FLOW
From Operations Rs m3561,274 27.9%  
From Investments Rs m-279-1,204 23.1%  
From Financial Activity Rs m-225-196 114.8%  
Net Cashflow Rs m-148-126 117.3%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 0.0 9.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 9.1 401.1%  
Shareholders   37,287 42,599 87.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 13, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS